Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
Demetri GD, Wang Y, Wehrle E, et al. J Clin Oncol.2009;27(19):3141-47.
This phase II randomized trial explored the relationship between imatinib plasma levels and clinical outcomes. The steady state Cmin values were associated with clinical benefits including time to progression and objective response.